PD-L1 expression, which is perhaps the most researched immune checkpoint receptor ligand, is reduced on glioma cells harboring a mutation of isocitrate dehydrogenase gene 1 (IDH1) and is increased after loss of phosphatase and tensin homolog (PTEN) (60, 62, 63). The gene discussed is PTEN; the disease is glioma.